Inflammatory bowel disease: Mechanisms, redox considerations, and therapeutic targets

Antioxidants and Redox Signaling

Volumn 19, Issue 14, 2013, Pages 1711-1747

  Biasi, Fiorella ^a   Leonarduzzi, Gabriella ^a   Oteiza, Patricia I ^b   Poli, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; AQUAPORIN; ASCORBIC ACID; AZATHIOPRINE; CAROTENOID; CATALASE; CERTOLIZUMAB PEGOL; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CRYOPYRIN; CYTOKINE; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; JUNCTIONAL ADHESION MOLECULE A; LIPOXIN; MERCAPTOPURINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROBIOTIC AGENT; RESOLVIN; RETINOIC ACID INDUCIBLE PROTEIN I; THIOREDOXIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHAGY; AUTOPHAGY RELATED GENE 16L; BACTERIAL COLONIZATION; BIOLOGICAL THERAPY; CADHERIN GENE; CASPASE RECRUITMENT DOMAIN GENE15; CORTICOSTEROID THERAPY; CROHN DISEASE; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; ENTERITIS; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GOBLET CELL; HUMAN; HUMAN LEUKOCYTE ANTIGEN CLASS II GENE; IMMUNITY RELATED GUANOSINE TRIPHOSPHATASE M GENE; IMMUNOTHERAPY; INTERLEUKIN 10 GENE; INTERLEUKIN 12P40 GENE; INTERLEUKIN 22 GENE; INTERLEUKIN 23R GENE; INTESTINE CELL; INTESTINE FLORA; INTESTINE MUCOSA; JANUS KINASE 2 GENE; LAMININ BETA1 GENE; LEUCINE RICH REPEAT KINASE 2 GENE; LIPID OXIDATION; MOLECULAR RECOGNITION; MUCIN 19 GENE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PANETH CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STAT3 GENE; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84882722472     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4530     Document Type: Article

References (300)

1. Aggarwal BB, Vijayalekshmi RV, and Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-Term friend, long-Term foe. Clin Cancer Res 15: 425-430, 2009
2. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, and Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A randomized controlled trial. Am J Gastroenterol 98: 348-353, 2003
3. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 783-801, 2006
4. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, and Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-Associated cancer. J Exp Med 207: 1045-1056, 2010
5. Anand PK, Tait SW, Lamkanfi M, Amer AO, Nunez G, Green DR, and Kanneganti TD. TLR2 and RIP2 pathways mediate autophagy of Listeria monocytogenes via ERK activation. J Biol Chem 286: 42981-42991, 2011
6. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Bü ning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van Den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, and Rioux JD. Meta-Analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246-252, 2011
7. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, and Rask-Madsen J. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54: 503-509, 2005
8. Ardite E, Sans M, Panés J, Romero FJ, Piqué JM, and Ferna ́ndez-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 80: 735-744, 2000
9. Ariel A, Chiang N, Arita M, Petasis NA, and Serhan CN. Aspirin-Triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-Alpha secretion from human T cells. J Immunol 170: 6266-6272, 2003
10. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, and Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6 trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102: 7671-7676, 2005
11. Artal-Sanz M and Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol Metab 20: 394-401, 2009
12. Asehnoune K, Strassheim D, Mitra S, Kim JY, and Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 172: 2522-2529, 2004
13. Balkis Budin S, Othman F, Louis SR, Abu Bakar M, Radzi M, Osman K, Das S, and Mohamed J. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. Rom J Morphol Embryol 50: 23-30, 2009
14. Banan A, Choudhary S, Zhang Y, Fields JZ, anf Keshavarzian A. Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line: Role of the microtubule cytoskeleton. Free Radic Biol Med 28: 727-738, 2000
15. Baregamian N, Song J, Bailey CE, Papaconstantinou J, Evers BM, and Chung DH. Tumor necrosis factor-Alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-Terminal kinase/p38 phosphorylation during necrotizing enterocolitis. Oxid Med Cell Longev 2: 297-306, 2009
16. Barksby HE, Lea SR, Preshaw PM, and Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149: 217-225, 2007
17. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, De Vos M, Vermeire S, Louis E, the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, and Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962, 2008
18. Baud V and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11: 372-377, 2001
19. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, and Schnurr M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59: 1192-1199, 2010
20. Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, Hugot JP, Daussy C, Verkarre V, Pigneur B, Fischer A, Klein C, Cerf-Bensussan N, and Ruemmele FM. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 106: 1544-1555, 2011
21. Beltrán B, Nos P, Dasí F, Iborra M, Bastida G, Martínez M, O'Connor JE, Sáez G, Moret I, and Ponce J. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis 16: 76-86, 2010
22. Bento AF, Claudino RF, Dutra RC, Marcon R, and Calixto JB. Omega-3 fatty acid-derived mediators 17(R) hydroxy docosahexaenoic acid, aspirin-Triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 187: 1957-1969, 2011
23. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner P, Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, and Watermeyer G. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 16: 112-124, 2010
24. Biasi F, Astegiano M, Maina M, Leonarduzzi G Poli G. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem 18: 4851-4865, 2011
25. Biasi F, Mascia C, Astegiano M, Chiarpotto E, Nano M, Vizio B, Leonarduzzi G, and Poli G. Pro-oxidant and proapoptotic effects of cholesterol oxidation products on human colonic epithelial cells: A potential mechanism of inflammatory bowel disease progression. Free Radic Biol Med 47: 1731-1741, 2009
26. Biasi F, Tessitore L, Zanetti D, Cutrin JC, Zingaro B, Chiarpotto E, Zarkovic N, Serviddio G, and Poli G. Associated changes of lipid peroxidation and transforminggrowth factor beta1 levels in human colon cancer during tumour progression. Gut 50: 361-367, 2002
27. Biasi F, Vizio B, Mascia C, Gaia E, Zarkovic N, Chiarpotto E, Leonarduzzi G, and Poli G. c-Jun N-Terminal kinase upregulation as a key event in the proapoptotic interaction between transforming growth factor-beta1 and 4-hydroxynonenal in colon mucosa. Free Radic Biol Med 41: 443-454, 2006
28. Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT, Johnson CP, Otterson MF, Telford GL, and Wilson KT. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 29: 881-888, 2000
29. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Erne P, Binder BR, and Leitinger N. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 99: 900-908, 2006
30. Brown AJ and Jessup W. Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med 30: 111-122, 2009
31. Brown SJ, Gianni D, Bokoch G, Mercer BA, Hodder P, and Rosen HR. Probe report for NOX1 inhibitors. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US), 2010. Bookshelf ID: NBK47342PMID:21433358
32. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171: 6164-6172, 2003
33. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, and O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 102: 439-448, 2007
34. Burrin DG and Stoll B. Emerging aspects of gut sulfur amino acid metabolism. Curr Opin Clin Nutr Metab Care 10: 63-68, 2007
35. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 75: 645-662, 2012
36. Cao W, Fiocchi C, and Pricolo VE. Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol 289: C1408-C1416, 2005
37. Carroll IM, Andrus JM, Bruno-Bárcena JM, Klaenhammer TR, Hassan HM, and Threadgill DS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 293: G729-G738, 2007
38. Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, and Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid- refractory ulcerative colitis: A multicentre study. Aliment Pharmacol Ther 35: 275-283, 2012
39. Chiva-Blanch G, Urpi-Sarda M, Llorach R, Rotches-Ribalta M, Guillén M, Casas R, Arranz S, Valderas- Martinez P, Portoles O, Corella D, Tinahones F, Lamuela-Raventos RM, Andres-Lacueva C, and Estruch R. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: A randomized clinical trial. Am J Clin Nutr 95: 326-334, 2012
40. Choi YJ, Seelbach MJ, Pu H, Eum SY, Chen L, Zhang B, Hennig B, and Toborek M. Polychlorinated biphenyls disrupt intestinal integrity via NADPH oxidase-induced alterations of tight junction protein expression. Environ Health Perspect 118: 976-981, 2010
41. Chouchana L, Narjoz C, Beaune P, Loriot MA, and Roblin X. Review article: Benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 35: 15-36, 2012
42. Circu ML and Aw TY. Redox biology of the intestine. Free Radic Res 45: 1245-1266, 2011
43. Clevers H. At the crossroads of inflammation and cancer. Cell 118: 671-674, 2004
44. Collingwood S and Witherington J. Therapeutic approaches towards the treatment of gastroinstestinal disorders. Drug News Perspect 20: 139-144, 2007
45. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, and Rutgeerts P. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010
46. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, and Powrie F. A functionally specialized population of mucosal CD103 + DCs induces Foxp3 + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764, 2007
47. Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Á lvarez A, Romero Vázquez J, and Herrerías Gutiérrez JM. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: A clinical series. Rev Esp Enferm Dig 103: 294-298, 2011
48. Corleto VD, Pagnini C, Margagnoni G, Guagnozzi D, Torre MS, Martorelli M, Latiano A, Annese V, Caprilli R, and Delle Fave G. IL-1beta-511 and IL-1RN.2 polymorphisms in inflammatory bowel disease: An Italian population study and meta-Analysis of European studies. Dig Liver Dis 42: 179-184, 2010
49. Cosnes J, Gower-Rousseau C, Seksik P, and Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140: 1785-1794, 2011
50. Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, and Ojcius DM. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem 282: 2871-2879, 2007
51. Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G, Pinho RA, Dal-Pizzol F, and Streck EL. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 22: 1846-1851, 2007
52. Danese S, Fiorino G, and Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-A therapy. Aliment Pharmacol Ther 34: 1-10, 2011
53. Danese S and Mantovani A. Inflammatory bowel disease and intestinal cancer: A paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 29: 3313-3323, 2010
54. Danese S, Sans M, and Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 53: 1035-1043, 2004
55. Danesi F, Philpott M, Huebner C, Bordoni A, and Ferguson LR. Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases. Mutat Res 690: 139-144, 2010
56. De Bacquer D, Clays E, Delanghe J, and De Backer G. Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. Atherosclerosis 189: 428-435, 2006
57. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Lö fberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, and Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When tostart, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199-212, 2011
58. D'Incà R, Cardin R, Benazzato L, Angriman I, Martines D, and Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 10: 23-27, 2004
59. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, and Akcay T. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci 52: 1636-1641, 2007
60. Dionne S, D'Agata ID, Hiscott J, Vanounou T, and Seidman EG. Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 112: 435-442, 1998
61. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677, 2008
62. Elrod JW, Laroux FS, Houghton J, Carpenter A, Ando T, Jennings MH, Grisham M, Walker N, and Alexander JS. DSS-induced colitis is exacerbated in STAT-6 knockout mice. Inflamm Bowel Dis 11: 883-889, 2005
63. Engler MB and Engler MM. The emerging role of flavonoid-rich cocoa and chocolate in cardiovascular health and disease. Nutr Rev 64: 109-118, 2006
64. Farhadi A, Keshavarzian A, Van De Kar LD, Jakate S, Domm A, Zhang L, Shaikh M, Banan A, and Fields JZ. Heightened responses to stressors in patients with inflammatory bowel disease. Am J Gastroenterol 100: 1796-1804, 2005
65. Fava F and Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J Gastroenterol 17:557-566, 2011
66. Feagins LA, Souza RF, and Spechler SJ. Carcinogenesis in IBD: Potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6: 297-305, 2009
67. Ferguson LR. Chronic inflammation and mutagenesis. Mutat Res 690: 3-11, 2010
68. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, and Rioux JD. Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet 4: E1000024, 2008
69. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, and Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 115: 3057-3071, 2005
70. Filippi J, Al-Jaouni R, Wiroth JB, Hébuterne X, and Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 12: 185-191, 2006
71. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, Suramanyam B, Guilford WJ, and Parkinson JF. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A 101: 15736-15741, 2004
72. Förstermann U and Mü nzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 113: 1708-1714, 2006
73. Fraga CG, Galleano M, Verstraeten SV, and Oteiza PI. Basic biochemical mechanisms behind the health benefits of polyphenols. Mol Aspects Med 31: 435-445, 2010
74. Franchi L, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim YG, and Núñez G. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol 10: 1-8, 2008
75. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J, and Rutgeerts P. Deficient hostbacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53: 987-992, 2004
76. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, the IBSEN study group, Mathew CG, and Schreiber S. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40: 1319-1323, 2008
77. Garat C and Arend WP. Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-Activated protein kinase and NF-kappaB pathways. Cytokine 23: 31-40, 2003
78. Garenc C, Julien P, and Levy E. Oxysterols in biological systems: The gastrointestinal tract, liver, vascular wall and central nervous system. Free Radic Res 44: 47-73, 2010
79. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, and Glimcher LH. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131: 33-45, 2007
80. Gelbmann CM, Leeb SN, Vogl D, Maendel M, Herfarth H, Scholmerich J, Falk W, and Rogler G. Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut 52: 1448-1456, 2003
81. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams IR, Neish AS, and Madara JL. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168: 5260-5267, 2002
82. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schä ffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hä tscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, and Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033-2045, 2009
83. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: Measurement, mechanism and the effects of nutrition. Mutat Res 443: 37-52, 1999
84. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, Nakamura T, Nakamura K, and Watanabe F. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis 44: 649-654, 2012
85. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, and Koide Y. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 1502-1506, 2006
86. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P and ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541-1549, 2002
87. Harizi H, Corcuff JB, and Gualde N. Arachidonic-Acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol Med 14: 461-469, 2008
88. Hatoum OA, Binion DG, Otterson MF, and Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 125: 58-69, 2003
89. Hausmann M, Kiessling S, Mestermann S, Webb G, Spö ttl T, Andus T, Schölmerich J, Herfarth H, Ray K, Falk W, and Rogler G. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122: 1987-2000, 2002
90. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin TH, Goodnow CC, and McGuckin MA. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PloS Med 5: E54, 2008
91. Heidemann J, Domschke W, Kucharzik T, and Maaser C. Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: A second line of defense? Infect Immun 74: 5425-5432, 2006
92. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Bü rgel N, Fromm M, Zeitz M, Fuss I, Strober W, and Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564, 2005
93. Hengstermann S, Valentini L, Schaper L, Buning C, Koernicke T, Maritschnegg M, Buhner S, Tillinger W, Regano N, Guglielmi F, Winklhofer-Roob BM, and Lochs H. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr 27: 571-578, 2008
94. Higashikubo A, Tanaka N, Noda N, Maeda I, Yagi K, Mizoguchi T, and Nanri H. Increase in thioredoxin activity of intestinal epithelial cells mediated by oxidative stress. Biol Pharm Bull 22: 900-903, 1999
95. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, MacDonald JA, and Beck PL. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17: 1359-1372, 2011
96. Holtmann MH and Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 20: 1-8, 2005
97. Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, and Lee YS. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 6: 5322-5331, 2006
98. Huang J, Canadien V, Lam GY, Steinberg BE, Dinauer MC, Magalhaes MA, Glogauer M, Grinstein S, and Brumell JH. Activation of antibacterial autophagy by NADPH oxidases. Proc Natl Acad Sci U S A 106: 6226-6231, 2009
99. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, and Kang JX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A 103: 11276-11281, 2006
100. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, and Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancerprone chronic inflammatory disease. Cancer Res 60: 3333-3337, 2000
101. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, Nos P, and Beltrán B. Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 39: 1102-1106, 2011
102. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, and Kagnoff MF. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 174: 4901-4907, 2005
103. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D; Western Regional Alliance for Pediatric IBD, Silber G, Wrobel I, Quiros A, the International IBD Genetics Consortium, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, the NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, De Vos M, Vermeire S, Louis E, the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Cardon R, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Silverberg MS, Satsangi J, and Hakonarson H. Common variants at five new loci associated with earlyonset inflammatory bowel disease. Nat Genet 41: 1335-1340, 2009
104. Ioannidis O, Varnalidis I, Paraskevas G, and Botsios D. Nutritional modulation of the inflammatory bowel response. Digestion 84: 89-101, 2011
105. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, and Azuma T. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodiuminduced colitis. Inflamm Bowel Dis 16: 87-95, 2010
106. Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab A, Hosoya T, Nomura A, Sakamoto T, Yamamoto M, and Sekizawa K. Transcription factor Nrf2 plays a pivotal role in protection against elastase induced pulmonary inflammation and emphysema. J Immunol 175: 6968-6975, 2005
107. Jeong W, Jung Y, Kim H, Park SJ, and Rhee SG. Thioredoxin-related protein 14, a new member of the thioredoxin family with disulfide reductase activity: Implication in the redox regulation of TNF-Alpha signaling. Free Radic Biol Med 47: 1294-1303, 2009
108. Jó zsef L, Zouki C, Petasis NA, Serhan CN, and Filep JG. Lipoxin A4 and aspirin-Triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 99: 13266-13267, 2002
109. Jung Y, Kim H, Min SH, Rhee SG, and Jeong W. Dynein light chain LC8 negatively regulates NF-kappaB through the redox-dependent interaction with IkappaBalpha. J Biol Chem 283: 23863-23871, 2008
110. Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF, and Patel DD. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 100: 414-423, 2005
111. Kanner J. Dietary advanced lipid oxidation endproducts are risk factors to human health. Mol Nutr Food Res 51: 1094-1101, 2007
112. Kaser A, Zeissig S, and Blumberg RS. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 28: 395-405, 2010
113. Kawanishi S, Hiraku Y, Pinlaor S, and Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387: 365-372, 2006
114. Kelsall B. Interleukin-10 in inflammatory bowel disease. N Engl J Med 361: 2091-2093, 2009
115. Kepp O, Galluzzi L, and Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol 12: 199-200, 2011
116. Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, and Fields JZ. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 52: 720-728, 2003
117. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, and Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and meta-Analysis. Am J Gastroenterol 106: 630-642, 2011
118. Khan MA, Steiner TS, Sham HP, Bergstrom KS, Huang JT, Assi K, Salh B, Tai IT, Li X, and Vallance BA. The single IgG IL-1-related receptor controls TLR responses in differentiated human intestinal epithelial cells. J Immunol 184: 2305-2313, 2010
119. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, and Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 66: 11580-11584, 2006
120. Khor TO, Huang M-T, Prawan A, Liu Y, Hao X, Yu S, Cheung WKL, Chan JY, Reddy BS, Yang CS, and Kong AN. Increased susceptibility of Nrf2 knockout mice to colitisassociated colorectal cancer. Cancer Prev Res 1: 187-191, 2008
121. Kim GS, Jung JE, Narasimhan P, Sakata H, and Chan PH. Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice. Neurobiol Dis 46: 440-449, 2012
122. Kim J, Cha Y-N, and Surh Y-J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mut Res 690: 12-23, 2010
123. Kim SW, Kim ES, Moon CM, Park JJ, Kim TI, Kim WH, and Cheon JH. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut 60: 1527-1536, 2011
124. Kim YS and Ho SB. Intestinal goblet cells and mucins in health and disease: Recent insights and progress. Curr Gastroenterol Rep 12: 319-330, 2010
125. Kimura H, Mukaida M, Kuwabara K, Ito T, Hashino K, Uchida K, Matsumoto K, and Yoshida K. 4-Hydroxynonenal modifies IgA in rat intestine after lipopolysaccharide injection. Free Radic Biol Med 41: 973-978, 2006
126. Kjellev S. The trefoil factor family-small peptides with multiple functionalities. Cell Mol Life Sci 66: 1350-1369, 2009
127. Kobayashi M and Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 7: 385-394, 2005
128. Kolios G, Valatas V, and Ward SG. Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Immunology 113: 427-437, 2004
129. Kong X, Thimmulappa R, Kombairaju P, and Biswal1 S. NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. J Immunol 185: 569-577, 2010
130. Koslowski MJ, Beisner J, Stange EF, and Wehkamp J. Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol 300: 34-40, 2010
131. Krieglstein CF, Anthoni C, Cerwinka WH, Stokes KY, Russell J, Grisham MB, and Granger DN. Role of bloodand tissue-Associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol 170: 490-496, 2007
132. Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CB, and Verspaget HW. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 201: 7-16, 2003
133. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, and Verspaget HW. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 201: 17-27, 2003
134. Kruidenier L, Kuiper I, Lamers CB, and Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: Semi-quantification, localization, and association with mucosal antioxidants. J Pathol 201: 28-36, 2003
135. Krupa LZ, Kennedy HJ, Jamieson CP, Fisher N, and Hart AR. The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: A review of practice at NHS teaching hospital. ISRN Gastroenterol 2011: 672017, 2011
136. Krzystek-Korpacka M, Neubauer K, Berdowska I, Zielinski B, Paradowski L, and Gamian A. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: Impact of anemia and treatment. Inflamm Bowel Dis 16: 1467-1475, 2010
137. Kucharzik T, Gewirtz AT, Merlin D, Madara JL, and Williams IR. Lateral membrane LXA4 receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium. Am J Physiol Cell Physiol 284: C888-C896, 2003
138. Kü hn R, Lö hler J, Rennick D, Rajewsky K, and Mü ller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993
139. Kuiper HC, Bruno RS, Traber MG, and Stevens JF. Vitamin C supplementation lowers urinary levels of 4-hydroperoxy-2-nonenal metabolites in humans. Free Radic Biol Med 50: 848-853, 2011
140. Kuwano Y, Tominaga K, Kawahara T, Sasaki H, Takeo K, Nishida K, Masuda K, Kawai T, Teshima-Kondo S, and Rokutan K. Tumor necrosis factor alpha activates transcription of the NADPH oxidase organizer 1 (NOXO1)gene and upregulates superoxide production in colon epithelial cells. Free Radic Biol Med 45: 1642-1652, 2008
141. Kwon KH, Ohigashi H, and Murakami A. Dextran sulfate sodium enhances interleukin-1 beta release via activation of p38 MAPK and ERK1/2 pathways in murine peritoneal macrophages. Life Sci 81: 362-371, 2007
142. Landberg R, Sun Q, Rimm EB, Cassidy A, Scalbert A, Mantzoros CS, Hu FB, and van Dam RM. Selected dietary flavonoids are associated with markers of inflammation and endothelial dysfunction in U.S. women. J Nutr 141: 618-625, 2011
143. Leach ST, Messina I, Lemberg DA, Novick D, Rubenstein M, and Day AS. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis 14: 68-74, 2008
144. Lee IA, Bae EA, Hyun YJ, and Kim DH. Dextran sulfate sodium and 2,4,6-Trinitrobenzene sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria in mice. J Inflamm (Lond) 7: 7, 2010
145. Legrand-Poels S, Kustermans G, Bex F, Kremmer E, Kufer TA, and Piette J. Modulation of Nod2-dependent NF-kappaB signaling by the actin cytoskeleton. J Cell Sci 120: 1299-1310, 2007
146. Lemaire S, Lizard G, Monier S, Miguet C, Gueldry S, Volot F, Gambert P, and Néel D. Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-,7beta-hydroxycholesterol, or 7-ketocholesterol. FEBS Lett 440: 434-439, 1998
147. Leonarduzzi G, Gamba P, Sottero B, Kadl A, Robbesyn F, Calogero RA, Biasi F, Chiarpotto E, Leitinger N, Sevanian A, and Poli G. Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic Biol Med 39: 1152-1161, 2005
148. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, and Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis. FASEB J 11: 851-857, 1997
149. Leonarduzzi G, Testa G, Sottero B, Gamba P, and Poli G. Design and development of nanovehicle based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 17: 74-95, 2010
150. Li H and Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41: 1-8, 2008
151. Li Q, Spencer NY, Oakley FD, Buettner GR, and Engelhardt JF. Endosomal Nox2 facilitates redox-dependent induction of NF-kappaB by TNF-Alpha. Antioxid Redox Signal 11: 1249-1263, 2009
152. Li Y, Mao Q, Shen L, Tian Y, Yu C, Zhu WM, and Li JS. Interleukin-23 receptor genetic polymorphisms and Crohn's disease susceptibility: A meta-Analysis. Inflamm Res 59: 607-614, 2010
153. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, Kundu K, Murthy N, Hansen JM, and Neish AS. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 47:1205-1211, 2009
154. Lipinski S, Till A, Sina C, Arlt A, Grasberger H, Schreiber S, and Rosenstiel P. DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci 122: 3522-3530, 2009
155. Liu Y, Hultén LM, and Wiklund O. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol 17: 317-323, 1997
156. Liu ZJ, Yadav PK, Su JL, Wang JS, and Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 15: 5784-5788, 2009
157. Lizard G, Lemaire S, Monier S, Gueldry S, Néel D, and Gambert P. Induction of apoptosis and of interleukin-1beta secretion by 7beta-hydroxycholesterol and 7-ketocholesterol: Partial inhibition by Bcl-2 overexpression. FEBS Lett 419: 276-280, 1997
158. Loguercio C, D'Argenio G, Delle Cave M, Cosenza V, Della Valle N, Mazzacca G, and Del Vecchio Blanco C. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis 35: 635-641, 2003
159. Loo YM and Gale M, Jr. Immune signaling by RIG-I-like receptors. Immunity 34: 680-692, 2011
160. Mangino MJ, Brounts L, Harms B, and Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 79: 84-92, 2006
161. Marcinkiewicz J, Ciszek M, Bobek M, Strus M, Heczko PB, Kurnyta M, Biedroń R, and Chmielarczyk A. Differential inflammatory mediator response in vitro from murine macrophages to lactobacilli and pathogenic intestinal bacteria. Int J Exp Pathol 88:155-164, 2007
162. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 40: 616-619, 2010
163. Mascia C, Maina M, Chiarpotto E, Leonarduzzi G, Poli G, and Biasi F. Proinflammatory effect of cholesterol and its oxidation products on CaCo-2 human enterocyte-like cells: Effective protection by epigallocatechin-3-gallate. Free Radic Biol Med 49: 2049-2057, 2010
164. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, and Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 40: 1107-1112, 2008
165. McGovern DP, Gardet A, Tö rkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lö rdal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, De Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, and Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 42: 332-337, 2010
166. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL, Schauer DB, Dedon PC, Fox JG, and Samson LD. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118: 2516-2525, 2008
167. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Löwer B, Wunderlich FT, von Kleist-Retzow JC, Waisman A, Westermann B, and Langer T. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev 22: 476-488, 2008
168. Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, Hochain P, Ducrotté P, Hecketsweiler B, Lerebours E, and Déchelotte P. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: The role of malnutrition. Clin Nutr 18: 313-317, 1999
169. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, and Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Methods 21: 200-208, 2011
170. Mishra S, Murphy LC, Nyomba BL, and Murphy LJ. Prohibitin: A potential target for new therapeutics. Trends Mol Med 11: 192-197, 2005
171. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W, and Schmitz G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) 84: 1055-1066, 2006
172. Moi P, Chan K, Asunis I, Cao A, and Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91: 9926-9930, 1994
173. Monteleone G, Boirivant M, Pallone F, and MacDonald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 1: S50-S53, 2008
174. Moore SF and MacKenzie AB. NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. J Immunol 183: 3302-3308, 2009
175. Morrison PJ, Ballantyne SJ, and Kullberg MC. Interleukin-23 and T helper 17-Type responses in intestinal inflammation: From cytokines to T-cell plasticity. Immunology 133: 397-408, 2011
176. Mukherjee A, Morosky SA, Shen L, Weber CR, Turner JR, Kim KS, Wang T, and Coyne CB. Retinoic acid-induced gene-1 (RIG-I) associates with the actin cytoskeleton via caspase activation and recruitment domain-dependent interactions. J Biol Chem 284: 6486-6494, 2009
177. Naftali T, Novick D, Gabay G, Rubinstein M, and Novis B. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation. Isr Med Assoc J 9: 504-508, 2007
178. Nair J, Gansauge F, Beger H, Dolara P, Winde G, and Bartsch H. Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis. Antioxid Redox Signal 8: 1003-1010, 2006
179. Nair MG, Guild KJ, Du Y, Zaph C, Yancopoulos GD, Valenzuela DM, Murphy A, Stevens S, Karow M, and Artis D. Goblet cell-derived resistin-like molecule beta augments CD4 + T cell production of IFN-gamma and infection-induced intestinal inflammation. J Immunol 181: 4709-4715, 2008
180. Naito Y, Takagi T, Ishikawa T, Handa O, Matsumoto N, Yagi N, Matsuyama K, Yoshida N, Yoshikawa T, and Kotake Y. Alpha-Phenyl-N-Tert-butylnitrone provides protection from dextran sulfate sodium-induced colitis in mice. Antioxid Redox Signal 4: 195-206, 2002
181. Naito Y, Takagi T, and Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol 42: 787-798, 2007
182. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, and Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12: 222-230, 2011
183. Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber A, and Hackam DJ. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 176: 3070-3079, 2006
184. Negre-Salvayre A, Auge N, Ayala V, Basaga H, Boada J, Brenke R, Chapple S, Cohen G, Feher J, Grune T, Lengyel G, Mann GE, Pamplona R, Poli G, Portero-Otin M, Riahi Y, Salvayre R, Sasson S, Serrano J, Shamni O, Siems W, Siow RC, Wiswedel I, Zarkovic K, and Zarkovic N. Pathological aspects of lipid peroxidation. Free Radic Res 44: 1125-1171, 2010
185. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 149: 173-186, 2007
186. Nijtmans LG, Artal SM, Grivell LA, and Coates PJ. The mitochondrial PHB complex: Roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci 59: 143-155, 2002
187. Nijtmans LG, De Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW, Muijsers AO, van der Spek H, and Grivell LA. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 19: 2444-2451, 2000
188. Nishikawa M, Oshitani N, Matsumoto T, Nishigami T, Arakawa T, and Inoue M. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer 93: 331-337, 2005
189. Nitti M, Domenicotti C, d'Abramo C, Assereto S, Cottalasso D, Melloni E, Poli G, Biasi F, Marinari UM, and Pronzato MA. Activation of PKC-beta isoforms mediates HNE-induced MCP-1 release by macrophages. Biochem Biophys Res Commun 294: 547-552, 2002
190. Nunes T, Fiorino G, Danese S, and Sans M. Familial aggregation in inflammatory bowel disease: Is it genes or environment? World J Gastroenterol 17: 2715-2722, 2011
191. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, and Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606, 2001
192. Oldenburg B, van Kats-Renaud H, Koningsberger JC, van Berge Henegouwen GP, and van Asbeck BS. Chemiluminescence in inflammatory bowel disease patients: A parameter of inflammatory activity. Clin Chim Acta 310: 151-156, 2001
193. Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, Yoshioka A, Totsuka T, Okamoto R, Nakamura T, Sakamoto N, Tsuchiya K, Aoki K, Ohya K, Yagita H, and Watanabe M. Signaling pathway via TNF-Alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-Associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 296: G850-G859, 2009
194. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, and Kensler TW. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 121: 1883-1891, 2007
195. Oshima N, Ishihara S, Rumi MA, Aziz MM, Mishima Y, Kadota C, Moriyama I, Ishimura N, Amano Y, and Kinoshita Y. A20 is an early responding negative regulator of toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 159: 185-198, 2010
196. Osman C, Merkwirth C, and Langer T. Prohibitins and the functional compartmentalization of mitochondrial membranes. J Cell Sci 122: 3823-3830, 2009
197. Otaegui-Arrazola A, Menéndez-Carreño M, Ansorena D, and Astiasarán I. Oxysterols: A world to explore. Food Chem Toxicol 48: 3289-3303, 2010
198. Pallone F and Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol 17: 307-312, 2001
199. Panaccione R, Loftus EV, Jr., Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, and Chao J. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 25: 419-425, 2011
200. Pasparakis M. IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol 1: S54-S57, 2008
201. Paul G, Khare V, and Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 42: 95-109, 2012
202. Perwez Ussain S, Hofseth LJ, and Harris CC. Radical causes of cancer. Nature Rev Cancer 3: 276-285, 2003
203. Poli G, Schaur RJ, Siems WG, and Leonarduzzi G. 4-hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med Res Rev 28: 569-631, 2008
204. Porath D, Riegger C, Drewe J, and Schwager J. Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines. J Pharmacol Exp Ther 315: 1172-1180, 2005
205. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, and Collins JE. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85: 1139-1162, 2005
206. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol 11: 2371-2384, 2005
207. Preiser JC, Van Gossum A, Berré J, Vincent JL, and Carpentier Y. Enteral feeding with a solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative stress. Crit Care Med 28: 3828-3832, 2000
208. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, Schoen RE, Yu J, and Zhang L. PUMAmediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest 121: 1722-1732, 2011
209. Raddatz D, Bockemü hl M, and Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: Relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17: 547-557, 2005
210. Ramasundara M, Leach ST, Lemberg DA, and Day AS. Defensins and inflammation: The role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24: 202-208, 2009
211. Rangamani P and Sirovich L. Survival and apoptotic pathways initiated by TNF-Alpha: Modeling and predictions. Biotechnol Bioeng 97: 1216-1229, 2007
212. Ravi A, Garg P, and Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: Boon or a bane? Inflamm Bowel Dis 13: 97-107, 2007
213. Rezaie A, Parker RD, and Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause? Dig Dis Sci 52: 2015-2021, 2007
214. Ricci S, Macchia G, Ruggiero P, Maggi T, Bossù P, Xu L, Medaglini D, Tagliabue A, Hammarström L, Pozzi G, and Boraschi D. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol 3: 15, 2003
215. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, and Gross V. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369, 1998
216. Rokutan K, Kawahara T, Kuwano Y, Tominaga K, Nishida K, and Teshima-Kondo S. Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol 30: 315-327, 2008
217. Romier B, Schneider YJ, Larondelle Y, and During A. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev 67: 363-378, 2009
218. Ryu JH, Kim SH, Lee HY, Bai JY, Nam YD, Bae JW, Lee DG, Shin SC, Ha EM, and Lee WJ. Innate immune homeostasis by the homeobox gene caudal and commensal-gut mutualism in Drosophila. Science 319: 777-782, 2008
219. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, and Akira S. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456: 264-268, 2008
220. Sands BE, Blank MA, Diamond RH, Barrett JP, and Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: Results from the ACCENT II study. Aliment Pharmacol Ther 23: 1127-1136, 2006
221. Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, Lefer DJ, and Alexander JS. Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic Biol Med 35: 1679-1687, 2003
222. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, Stein K, and Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 682: 39-53, 2009
223. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, and Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26:1749-1760, 2007
224. Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, and Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 151: 528-535, 2008
225. Seidelin JB and Nielsen OH. Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol 17: 363-369, 2005
226. Serhan CN. The resolution of inflammation: The devil in the flask and in the details. FASEB J 25: 1441-1448, 2011
227. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204, 2000
228. Serhan CN and Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 6: 1191-1197, 2005
229. Seth RB, Sun L, Ea CK, and Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682, 2005
230. Sharma A and Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci U S A 101: 17492-17497, 2004
231. Sheng YH, Hasnain SZ, Florin TH, and McGuckin MA. Mucins in inflammatory bowel diseases and colorectal cancer. J Gastroenterol Hepatol 27: 28-38, 2012
232. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, and Omata M. Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 179: 2681-2685, 2007
233. Shimozawa M, Naito Y, Manabe H, Uchiyama K, Kuroda M, Katada K, Yoshida N, and Yoshikawa T. 7-Ketocholesterol enhances the expression of adhesion molecules on human aortic endothelial cells by increasing the production of reactive oxygen species. Redox Rep 9: 370-375, 2004
234. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, and Dröge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 42: 485-492, 1998
235. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, and Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-Alpha production. Am J Physiol Regul Integr Comp Physiol 281: R1264-R1273, 2001
236. Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Paré P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, and Duerr RH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 41: 216-220, 2009
237. Slavova N, Drescher A, Visekruna A, Dullat S, Kroesen AJ, Ritz JP, and Buhr HJ. NALP expression in Paneth cells provides a novel track in IBD signaling. Langenbecks Arch Surg 395: 351-357, 2010
238. Song YA, Park YL, Yoon SH, Kim KY, Cho SB, Lee WS, Chung IJ, and Joo YE. Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-jB and JNK activation in intestinal epithelial cells. Inflamm Res 60: 493-500, 2011
239. Sono K, Yamada A, Yoshimatsu Y, Takada N, and Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine 59: 410-416, 2012
240. Sorbara MT and Girardin SE. Mitochondrial ROS fuel the inflammasome. Cell Res 21: 558-560, 2011
241. Sottero B, Gamba P, Gargiulo S, Leonarduzzi G, and Poli G. Cholesterol oxidation products and disease: An emerging topic of interest in medicinal chemistry. Curr Med Chem 16: 685-705, 2009
242. Sripathi SR, He W, Atkinson CL, Smith JJ, Liu Z, Elledge BM, and Jahng WJ. Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry 50: 8342-8351, 2011
243. Stables MJ and Gilroy DW. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res 50: 35-51, 2011
244. Steglich G, Neupert W, and Langer T. Prohibitins regulate membrane protein degradation by the m-AAA protease in mitochondria. Mol Cell Biol 19: 3435-3442, 1999
245. Sung SC, Kim K, Lee KA, Choi KH, Kim SM, Son YH, Moon YS, Eo SK, and Rhim BY. 7-Ketocholesterol upregulates interleukin-6 via mechanisms that are distinct from those of tumor necrosis factor-Alpha, in vascular smooth muscle cells. J Vasc Res 46: 36-44, 2009
246. Surh J, Lee S, and Kwon H. 4-hydroxy-2-Alkenals in polyunsaturated fatty acids-fortified infant formulas and other commercial food products. Food Addit Contam 24: 1209-1218, 2007
247. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, Ohtsuka K, Honma T, Narisawa R, and Asakura H. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 36: 1301-1306, 2001
248. Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B, Kovari E, Herrmann F, Hadengue A, and Krause KH. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol 207: 164-176, 2005
249. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, and Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 232: 799-808, 2007
250. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, Takahashi H, Takahashi S, Kinouchi Y, Hiwatashi N, Funayama Y, Sasaki I, Tsuji I, and Shimosegawa T. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomizedcontrolled trial. Aliment Pharmacol Ther 24: 1333-1340, 2006
251. Takahashi Y, Masuda H, Ishii Y, Nishida Y, Kobayashi M, and Asai S. Decreased expression of thioredoxin interacting protein mRNA in inflamed colonic mucosa in patients with ulcerative colitis. Oncol Rep 18: 531-535, 2007
252. Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, Okazaki K, Yodoi J, and Chiba T. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 131: 1110-1121, 2006
253. Tardieu D, Jaeg JP, Cadet J, Embvani E, Corpet DE, and Petit C. Dextran sulfate enhances the level of an oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in rat colonic mucosa. Cancer Lett 134: 1-5, 1998
254. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, and Petit CR. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976, 2000
255. Targan SR and Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 206: 296-305, 2005
256. te Velde AA, Pronk I, De Kort F, and Stokkers PCF. Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: An important role for H2O2? Eur J Gastroenterol Hepatol 20: 555-560, 2008
257. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, and Ernst M. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8: 1089-1097, 2002
258. Teng X, Xu LF, Zhou P, Sun HW, and Sun M. Effects of trefoil peptide 3 on expression of TNF-Alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation 32: 120-129, 2009
259. Theiss AL, Jenkins AK, Okoro NI, Klapproth JM, Merlin D, and Sitaraman SV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Mol Biol Cell 20: 4412-4423, 2009
260. Theiss AL, Idell RD, Srinivasan S, Klapproth JM, Jones DP, Merlin D, and Sitaraman SV. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J 21: 197-206, 2007
261. Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, Merlin D, and Sitaraman SV. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis 17: 1163-1176, 2011
262. Theiss AL, Obertone TS, Merlin D, and Sitaraman SV. Interleukin-6 transcriptionally regulates prohibitin expression in intestinal epithelial cells. J Biol Chem 282: 12804-12812, 2007
263. Theiss AL and Sitaraman SV. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 1813: 1137-1143, 2011
264. Theiss AL, Vijay-Kumar M, Obertone TS, Jones DP, Hansen JM, Gewirtz AT, Merlin D, and Sitaraman SV. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 137: 199-208, 2009
265. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, Ziegler R, and Nawroth PP. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/ IkappaBalpha system in patients with Crohn's disease. Gut 45: 693-704, 1999
266. Thimmulappa R, Lee H, Rangasamy T, Reddy S, Yamamoto M, Kensler T, and Biswal S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116: 984-995, 2006
267. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, 3rd, and Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884, 2010
268. Toruner M, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, and Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929-936, 2008
269. Ullman TA and Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816, 2011
270. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Bü ller HA, Dekker J, Van Seuningen I, Renes IB, and Einerhand AW. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-129, 2006
271. Van Limbergen J, Russell RK, Nimmo ER, and Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol 102: 2820-2831, 2007
272. Vetrano S,RescignoM,CeraMR,CorrealeC,RumioC,DoniA, Fantini M, SturmA, Borroni E, Repici A, Locati M, MalesciA, Dejana E, and Danese S. Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 135: 173-184, 2008
273. Villani AC,LemireM, FortinG,Louis E, Silverberg MS,Collette C, Baba N, Libioulle C, Belaiche J, BittonA,GaudetD,CohenA, LangelierD, Fortin PR, Wither JE, SarfatiM, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, and Franchimont D. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 41: 71-76, 2009
274. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, and Steinhoff U. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 116: 3195-3203, 2006
275. Vladykovskaya E, Ozhegov E, Hoetker JD, Xie Z, Ahmed Y, Suttles J, Srivastava S, Bhatnagar A, and Barski OA. Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids. J Lipid Res 52: 2209-2225, 2011
276. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, and Wallace JL. Up-regulation of annexin-A1 and lipoxin a(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One 7: E39244, 2012
277. Vora P, Youdim A, Thomas LS, Fukata M, Tesfay SY, Lukasek K, Michelsen KS, Wada A, Hirayama T, Arditi M, and Abreu MT. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 173: 5398-5405, 2004
278. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schröder JM, and Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 281: 2005-2011, 2006
279. Cromer WE, Mathis JM, Granger DN, Chaitanya GV, and Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 17: 578-593, 2011
280. Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, Russell RK, Sleiman PM, Imielinski M, Glessner J, Hou C, Wilson DC, Walters T, Kim C, Frackelton EC, Lionetti P, BarabinoA, Van Limbergen J,Guthery S,Denson L, Piccoli D, LiM, Dubinsky M, Silverberg M, Griffiths A, Grant SF, Satsangi J, Baldassano R, and Hakonarson H. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 84: 399-405, 2009
281. Wang Y and Bogenhagen DF. Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane. J Biol Chem 281: 25791-25802, 2006
282. Weber CK, Liptay S, Wirth T, Adler G, and Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119: 1209-1218, 2000
283. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Jr., Fellermann K, Ganz T, Stange EF, and Bevins CL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102: 18129-18134, 2005
284. Wehkamp J, Schmid M, Fellermann K, and Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 77: 460-465, 2005
285. Wells JM, Rossi O, Meijerink M, and van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 108: 4607-4614, 2011
286. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, Walsh MC, Choi Y, Shadel GS, and Ghosh S. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472: 476-480, 2011
287. Weylandt KH, Kang JX, Wiedenmann B, and Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 13: 797-799, 2007
288. Wullaert A, Bonnet MC, and Pasparakis M. NF-jB in the regulation of epithelial homeostasis and inflammation. Cell Res 21: 146-158, 2011
289. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, and Eissa NT. Toll-like receptor 4 is a sensor for au- tophagy associated with innate immunity. Immunity 27: 135-144, 2007
290. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, and Akira S. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169: 6668-6672, 2002
291. Yamamoto-Furusho JK, Santiago-Hernández JJ, Pérez- Hernández N, Ramírez-Fuentes S, Fragoso JM, and Vargas-Alarcón G. Interleukin 1 b (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol 45: 531-535, 2011
292. Ye D and Ma TY. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-Alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med 12: 1331-1346, 2008
293. Yoshida H, Russell J, Senchenkova EY, Almeida Paula LD, and Granger DN. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 177: 2774-2781, 2010
294. You Y, Fu JJ, Meng J, Huang GD, and Liu YH. Effect of Nacetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. Dig Dis Sci 54: 1643-1650, 2009
295. Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, and Papadakis KA. Expression and functional characterization of FOXP3 + CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 13: 191-199, 2007
296. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, and Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32: 379-391, 2010
297. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, and Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453: 236-240, 2008
298. Zhou R, Tardivel A, Thorens B, Choi I, and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140, 2010
299. Zhou R, Yazdi AS, Menu P, and Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225, 2011
300. Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, Urowitz MB, Fortin PR, and Wither JE. Altered expression of TNF-Alpha signaling pathway proteins in systemic lupus erythematosus. J Rheumatol 37: 1658-1666, 2010